Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 18/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21175740 | 0.83 | HDAC4 (0.57) | HDAC6HDAC1HDAC8HDAC4 | |
| SCHEMBL21175806 | 0.81 | HDAC4 (0.50) | HDAC6HDAC1HDAC8HDAC4 | |
| SCHEMBL21175729 | 0.79 | HDAC4 (0.51) | HDAC6HDAC1HDAC8HDAC4 | |
| SCHEMBL21175923 | 0.79 | HDAC4 (0.54) | HDAC6HDAC1HDAC8HDAC4 | |
| SCHEMBL21175721 | 0.79 | HDAC4 (0.48) | HDAC6HDAC1HDAC8HDAC4 | |
| SCHEMBL21175653 | 0.77 | HDAC4 (0.47) | HDAC6HDAC1HDAC4 | |
| SCHEMBL19100146 | 0.77 | HDAC4 (0.61) | HDAC6HDAC4 | |
| SCHEMBL25664097 | 0.77 | HDAC4 (0.55) | HDAC6HDAC1HDAC8HDAC4 | |
| SCHEMBL21175751 | 0.77 | HDAC4 (0.46) | HDAC6HDAC1HDAC8HDAC4 | |
| SCHEMBL21190161 | 0.76 | HDAC4 (0.57) | HDAC6HDAC8HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11026427-B2 | Microbiocidal oxadiazole derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2021-06-08 | — | — | US | disclosed |
| US-11026427-B2 | Microbiocidal oxadiazole derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2021-06-08 | — | — | US | disclosed |
| US-20190223441-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2019-07-25 | — | — | US | disclosed |
| US-20190223441-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190223441-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | PRF1, NOX3, NOX1 | HDAC6 612/4885HDAC1 526/4885HDAC8 1720/4885 |
| US-11026427-B2 | Microbiocidal oxadiazole derivatives | PRF1, NOX3, NOX1 | HDAC6 612/4885HDAC1 526/4885HDAC8 1720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.